pharmaceuticals

Is Neurotrope the Default Alzheimer’s Winner After Biogen’s Implosion?

Neurotrope Inc. (NASDAQ: NTRP) may be a winner by default in the battle against Alzheimer's disease after shares of Biogen Inc. (NASDAQ: BIIB) suffered handily with the announcement that it ...
Read Full Story »

Why Pfizer Is Getting Deeper Into Gene Therapy

Pfizer Inc. (NYSE: PFE) is getting deeper into gene therapy. The U.S. drug giant has acquired a 15% stake in Vivet Therapeutics. On top of the investment in the French ...
Read Full Story »

Pfizer Moves Over Half a Billion for Wilson Disease Treatment

Pfizer Inc. (NYSE: PFE) has announced that it has acquired a 15% equity interest in Vivet and secured an exclusive option to acquire all outstanding shares. Pfizer is looking to ...
Read Full Story »

Bad News for AbbVie and Multiple Myeloma Patients

AbbVie Inc. (NYSE: ABBV) and patients suffering from multiple myeloma have seen some additional bad news. The Food and Drug Administration (FDA) has placed a partial clinical hold on clinical ...
Read Full Story »

How Much More Talc Fallout Will Johnson & Johnson Face After This $29 Million Verdict?

A California jury has awarded $29 million to a woman who claimed talcum-powder-based Johnson & Johnson (NYSE: JNJ) products caused her cancer. This ruling is the most recent defeat, out of ...
Read Full Story »

Big Pharma Short Interest Backs Off, With One Huge Exception

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Great News for Adolescents with Moderate to Severe Atopic Dermatitis

In an incredible move for adolescent patients 12 to 17 years of age, the U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for patients with moderate-to-severe atopic dermatitis. ...
Read Full Story »

Wedbush’s Top Biotech Picks Ahead of AACR Annual Meeting

The American Association for Cancer Research (AACR) annual meeting is scheduled for March 31 to April 3. Abstracts have been released for the companies presenting at this event, and Wedbush ...
Read Full Story »

Major Pharma Sees Tremendous Rise in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

What Ipsen Wants From Clementia Pharmaceuticals

Clementia Pharmaceuticals Inc. (NASDAQ: CMTA) shares shot up on Monday after the firm announced that it will be acquired. The firm has entered into an agreement to be acquired by ...
Read Full Story »

Why This New Collaboration Is Incredible for Voyager Therapeutics

On Friday, Voyager Therapeutics Inc. (NASDAQ: VYGR) announced a collaboration with pharma giant AbbVie Inc. (NYSE: ABBV) to develop and commercialize vectorized antibodies directed at pathological species of alpha-synuclein for ...
Read Full Story »

Johnson & Johnson and Other Health Care Stocks With Recent Death Crosses

Golden crosses and death crosses are common signals in technical analysis and refer to the relationship between short-term and long-term moving averages. The golden cross typically is seen as a ...
Read Full Story »

Is Merck Overpaying for Immune Design?

Immune Design Corp. (NASDAQ: IMDZ) shares absolutely exploded on Thursday after Merck & Co. Inc. (NYSE: MRK) announced that it would be acquiring the firm at what some might call ...
Read Full Story »

Who’s to Blame for the US Opioid Epidemic

For more than half a decade, the United States has seen an incredible rise of an opioid epidemic within its borders. Fatal overdoses have claimed the lives of many as ...
Read Full Story »

Huge Johnson & Johnson Acquisition Targets Robotics

On Wednesday, Johnson & Johnson (NYSE: JNJ) announced that its subsidiary, Ethicon, had entered a definitive agreement to acquire Auris Health, a robotic technology firm, initially focused on lung cancer. Management ...
Read Full Story »